Concepedia

Nicolas Hohmann

NH

24

Publications

1.2K

Citations

19

H-Index

2012

Active since

Affiliations

Heidelberg University(Current)

University Hospital Heidelberg

National Center for Tumor Diseases

German Cancer Research Center

Vaximm (Germany)

Nicolas Hohmann is an author at Heidelberg University specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2012–2023

24

Publications

24

First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B

Antje Blank, Christoph Markert, Nicolas Hohmann et al. · Journal of Hepatology · 2016 · 214 citations

, , +6

A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

Birte Halama, Nicolas Hohmann, Jürgen Burhenne et al. · Clinical Pharmacology & Therapeutics · 2013 · 87 citations

The NTCP‐inhibitor Myrcludex B: Effects on Bile Acid Disposition and Tenofovir Pharmacokinetics

Antje Blank, Annette Eidam, Mathias Haag et al. · Clinical Pharmacology & Therapeutics · 2017 · 78 citations

Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial

Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Andreas G. Niethammer et al. · OncoImmunology · 2015 · 72 citations · Full text

A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer

Friedrich H. Schmitz-Winnenthal, Nicolas Hohmann, Thomas Schmidt et al. · OncoImmunology · 2017 · 71 citations · Full text

Rows per page

1–5 of 24